a randomised trial in 726 postmenopausal women hormone receptor-positive HER2-negative advanced breast cancer who had previous endocrine therapy. This compared patients treated with Kisqali plus ...

Pfizer’s drug was also recently approved for use in pre- and peri-menopausal women with advanced breast ... up in the category with Novartis’ Kisqali (ribociclib), which got a green light ...

Reham Sabri Thawabi, AGM, senior director of Premium Banking of Commercial Bank, said: “As a woman in the banking sector, I am proud to take part in Commercial Bank’s seminar as it served as a ...

Image Credit: Shutterstock Cairo: A Saudi court has sentenced a woman to two months in prison and ordered her to pay a fine of SR40,000 for violating the kingdom's anti-commercial cover-up system.

Pictures: Maura Hickey Hosted by Jess Kelly, technology correspondent at Newstalk and Connected magazine columnist, the event was attended by 400 guests and celebrated the incredible achievements and ...

In the EU, Kisqali is approved for the treatment of women with HR+/HER2- advanced or MBC in combination with either an AI or fulvestrant as initial ET or following disease progression15.

In the US, Kisqali is indicated for the treatment of adults with HR+/HER2- advanced or MBC in combination with an AI as initial ET or fulvestrant as initial ET or following disease progression on ET ...

Reham Sabri Thawabi, AGM, Senior Director of Premium Banking of Commercial Bank, said: “As a woman in the banking sector, I am proud to take part of Commercial Bank’s seminar as it served as a ...